We present 2 patients with hyperferritinemia, increased liver iron and hemochromatosis-associated HFE genotypes. At diagnosis, both patients had chronic anemia that prevented initiation of phlebotomy. Iron chelation with deferasirox proved to be a safe and effective means of substantially lowering ferritin levels.

Keywords:
Deferasirox, HFE hemochromatosis, Iron chelation
1.
Pietrangelo A: Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010;139:393–408, 408e 391–392.
2.
Adams PC, Barton JC: How I treat hemochromatosis. Blood 2010;116:317–325.
3.
Meerpohl JJ, Antes G, Rucker G, Fleeman N, Niemeyer C, Bassler D: Deferasirox for managing transfusional iron overload in people with sickle cell disease. Cochrane Database Syst Rev 2010:CD007477.
4.
Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates TD: The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010;116:537–543.
5.
Portmann BC, Thompson RJ, Roberts EA, Paterson AC: Genetic and metabolic liver disease; in Burt AD, Portmann BC, Ferrell LD (eds): MacSweens’s Pathology of the Liver. London, Elsevier, 2005, vol 5, pp 199–326.
6.
Wick M, Pinggera G, Lehmann P: Clinical Aspects and Laboratory. Iron Metabolism, Anemias: Novel Concepts in the Anemias of Malignancies and Renal and Rheumatoid Diseases. Wien, Springer, 2009.
7.
Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, Gross J, Malfertheiner P, McLaren GD, Niederau C, Piperno A, Powell LW, Russo MW, Stoelzel U, Stremmel W, Griffel L, Lynch N, Zhang Y, Pietrangelo A: A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010;52:1671–1779.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.